# Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections

> **NCT03814616** · PHASE2 · UNKNOWN · sponsor: **Shin Poong Pharmaceutical Co. Ltd.** · enrollment: 300 (actual)

## Conditions studied

- Malaria,Falciparum

## Interventions

- **DRUG:** Pyronaridine tetraphosphate 180mg:artesunate 60mg

## Key facts

- **NCT ID:** NCT03814616
- **Lead sponsor:** Shin Poong Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-03
- **Primary completion:** 2019-10
- **Final completion:** 2019-10
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2019-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03814616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03814616, "Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03814616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*